Show simple item record

dc.contributor.authorSkates, Steven J
dc.contributor.authorGreene, Mark H.
dc.contributor.authorBuys, Saundra S
dc.contributor.authorMai, Phuong L
dc.contributor.authorBrown, Powel
dc.contributor.authorPiedmonte, Marion
dc.contributor.authorRodriguez, Gustavo
dc.contributor.authorSchorge, John O
dc.contributor.authorSherman, Mark
dc.contributor.authorDaly, Mary B
dc.contributor.authorRutherford, Thomas
dc.contributor.authorBrewster, Wendy R
dc.contributor.authorO'Malley, David M
dc.contributor.authorPartridge, Edward
dc.contributor.authorBoggess, John
dc.contributor.authorDrescher, Charles W
dc.contributor.authorIsaacs, Claudine
dc.contributor.authorBerchuck, Andrew
dc.contributor.authorDomchek, Susan
dc.contributor.authorDavidson, Susan A
dc.contributor.authorEdwards, Robert
dc.contributor.authorElg, Steven A
dc.contributor.authorWakeley, Katie
dc.contributor.authorPhillips, Kelly-Anne
dc.contributor.authorArmstrong, Debroah
dc.contributor.authorHorowitz, Ira
dc.contributor.authorFabian Carol J
dc.contributor.authorWalker, Joan
dc.contributor.authorSluss, Patrick M
dc.contributor.authorWelch, William
dc.contributor.authorMinasian, Lori
dc.contributor.authorHorick, Nora K
dc.contributor.authorKasten, Carol H
dc.contributor.authorNayfield, Susan
dc.contributor.authorAlberts, David
dc.contributor.authorFinkelstein, Dianne M
dc.contributor.authorLu, Karen H
dc.date.accessioned2017-11-03T23:40:59Z
dc.date.available2017-11-03T23:40:59Z
dc.date.issued2017-01-31
dc.identifier.citationSkates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P., Piedmonte, M., . . . Lu, K. H. (2017). Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. Clinical Cancer Research, 23(14), 3628-3637.en
dc.identifier.doi10.1158/1078-0432.CCR-15-2750
dc.identifier.urihttp://hdl.handle.net/10150/625973
dc.description.abstractPurpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL. Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject’s baseline, which triggered transvaginal ultrasound. Specificity and PPV were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls.
dc.description.sponsorshipThe ROCA study was supported mainly by research grants/contracts from NCI to sites in the Cancer Genetics Network, the Ovarian SPORE program, and the Early Detection Research Network (CA078284 D. Finkelstein, CA078134 H. Anton-Culver, CA078164 D. Bowen, CA078156 S. Domchek, CA078148 C. Griffin, CA078146 C. Isaacs, CA078174 G. Mineau, CA078157 J. Schildkraut, CA078142 L. Strong, HHSN2612007440000C D. Finkelstein, CA083638 R. Ozols, CA083591 E. Partridge, CA086389 H. Lynch); Fujirebio Diagnostics Inc supported the CGN study for one year after NCI funding ended. Drs. P. Mai and M. Greene were supported by the Intramural Research Program, NCI/NIH. The Gynecologic Oncology Group’s study (GOG-0199) was supported by intramural research funds from the Clinical Genetics Branch, and National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank (CA027469 P. Di Saia), the GOG Statistical and Data Center (CA037517 J. Blessing), and by NCI’s Community Clinical Oncology Program (CCOP) grant (CA101165 P. Di Saia). Participation by the investigators of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG) is gratefully acknowledged. K-A. Phillips is an Australian National Breast Cancer Foundation Fellow.en
dc.language.isoenen
dc.publisherAmerican Association for Cancer Researchen
dc.rightsCopyright © 2017, American Association for Cancer Research.en
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectEarly Detectionen
dc.subjectCancer Screeningen
dc.subjectOvarian Canceren
dc.subjectBiomarker Algorithmen
dc.subjectBRAC 1/2en
dc.titleEarly detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk-combined results from two screening trialsen
dc.typeArticleen
dc.contributor.departmentMassachusetts General Hospital, Boston, MAen
dc.contributor.departmentNational Cancer Institute, Rockville, MDen
dc.contributor.departmentHuntsman Cancer Institute, University of Utah, School of Medicine, Salt Lake City, UTen
dc.contributor.departmentMD Anderson Cancer Center, Houston, TXen
dc.contributor.departmentRoswell Park Cancer Institute, Buffalo, NYen
dc.contributor.departmentNorthShore University Health System, Evanston, ILen
dc.contributor.departmentFox Chase Cancer Center, Philadelphia, PAen
dc.contributor.departmentUniversity of South Florida, Tampa, FLen
dc.contributor.departmentUniversity of North Carolinia, Chapel Hill, NCen
dc.contributor.departmentOhio State University and the James Cancer Center, Columbus, OHen
dc.contributor.departmentUniversity of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, ALen
dc.contributor.departmentRex Cancer Center, Raleigh, NCen
dc.contributor.departmentFred Hutchinson Cancer Research Center, Seattle, WAen
dc.contributor.departmentGeorgetown University Medical Center, Lombardi Cancer Center, Washington, DCen
dc.contributor.departmentDuke University Medical Center, Division of Gynecologic Oncology, Durham, NCen
dc.contributor.departmentUniversity of Pennsylvania, Abramson Cancer Center, Philadelphia, PAen
dc.contributor.departmentDenver Health Medical Center, Denver, COen
dc.contributor.departmentMagee-Womens Hospital, Pittsburgh, PAen
dc.contributor.departmentThe Iowa Clinic, Gynecologic Oncology, Des Moines, IAen
dc.contributor.departmentDana-Farber Cancer Center in Clinical Affiliation with South Shore Hospital, South Weymouth, MAen
dc.contributor.departmentDivision of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australiaen
dc.contributor.departmentSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australiaen
dc.contributor.departmentCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australiaen
dc.contributor.departmentJohns Hopkins Kimmel Cancer Center, Baltimore, MDen
dc.contributor.departmentEmory University School of Medicine, Atlanta, GAen
dc.contributor.departmentThe University of Kansas Cancer Center, Westwood, KSen
dc.contributor.departmentStephenson Cancer Center, University of Oklahoma HSC, Oklahoma City, OKen
dc.contributor.departmentBrigham and Women's Hospital, Boston, MAen
dc.contributor.departmentFood and Drug Administration, Silver Spring, MDen
dc.contributor.departmentUniversity of Florida, Gainseville, FLen
dc.contributor.departmentUniversity of Arizona Cancer Center, Tucson, AZen
dc.identifier.journalClinical Cancer Researchen
dc.description.note12 month embargo; Published OnlineFirst January 31, 2017en
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en
dc.eprint.versionFinal accepted manuscripten
refterms.dateFOA2018-02-01T00:00:00Z
html.description.abstractPurpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL. Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject’s baseline, which triggered transvaginal ultrasound. Specificity and PPV were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls.


Files in this item

Thumbnail
Name:
Alberts_Early_Detection.pdf
Size:
774.6Kb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record